2011

05-08 November 2011, Madrid – Spain at ISPOR Europe 2011

Podium presentation

  • view > Key market access drivers for a successful health technology appraisal outcome – the case of rheumatoid arthritis

Workshop

  • view > Overcoming the complexity of an increasingly fragmented regional and local market access requirement

Posters

  • view > Switch of prescription drugs to the Over-The-Counter status (Rx-to-OTC): the development of a flexible and generic European budget impact model
  • view > Cross-sectional analysis of ambulatory care expenditure among patients with type 2 diabetes mellitus (T2DM) according to treatment stage and renal function in France using EGB database
  • view > What are the key drivers for changing HTA decisions? Example of Alzheimer’s disease treatment in Germany, France and UK
  • view > Reimbursing telemonitoring in Europe: are payers ready?
  • view > The economic impact of switches of prescription drugs to the Over-the-Counter status (Rx-to-OTC): a systematic literature review
  • view > The Huntington clinical self-reported instrument (H-CSRI): cross-cultural validation in Germany, Poland and USA
  • view > The Huntington Quality of Life Instrument (H-QoL-I): cross-cultural validation in Germany, Poland and USA
  • view > International comparison of Huntington disease (HD) burden
  • view > A literature review on utility values associated with HPV-related diseases
  • view > How have quality checklists improved the quality of published economic evaluations? An example of venous thromboembolism (VTE) prophylaxis
  • view > Predicting EQ-5D utility scores from the Huntington Quality of Life Instrument (H-QOL-I)
  • view > Describing and comparing utility from EQ-5D and SF-6D in a Huntington’s disease population
  • view > Preliminary analysis of the unwritten decision rules behind the French Transparency Commission’s assessment of drugs
  • view > Quality of life as a predictor of clinical outcome: example in schizophrenia
  • view > Comparison of the SF-6D and the EQ-5D in patients with schizophrenia
  • view > Methodological challenges for economic evaluations of vaccination programs: the case of pertussis booster vaccination
  • view > Evaluation of bivariate meta-analysis methods to synthesise results of several studies with two correlated endpoints

11-14 September 2011, Melbourne – Australia at World Congress of Huntington Disease

Posters

  • view > Burden of Huntington disease in USA
  • view >  International comparison of Huntington disease (HD) burden
  • view > Cross-cultural validation of the Huntington Quality of Life Instrument (H-QoL-I)
  • view >  Burden of Huntington’s disease in Poland
  • view >  Validation of the Huntington Clinical Self-Reported Instrument (H-CSRI), a clinimetric patient assessed scale for patients with huntington’s disease

10-13 July 2011, Toronto – Canada at iHEA 8th World Congress: Planned Enhancements

Presentations

  • Cost-effectiveness of rasagiline monotherapy aimed at disease modulation in patients with Parkinson’s disease in Norway
    available upon request

Posters

  • view > Evaluation of Bayesian bivariate meta-analysis to synthesise results of several studies with two correlated endpoints
  • view > Relationship between utility and the positive and negative syndrome scale for Schizophrenia in the United Kingdom, France and Germany -- Findings from the European Schizophrenia Cohort (EuroSC)

21-25 May 2011, Baltimore – MD, USA at ISPOR International

Posters

  • view > PND29 - Validation of the Huntington clinical self-reported instrument (H-CSRI), a clinimetric patient assessed scale for patients with Huntington’s disease
  • view > PMD23 - Partial Responders in schizophrenia
  • view > PMH73 - Retrospective analysis of the impact of persistence on health care changes among opioid-dependent patients treated with buprenorphine/Naloxone using an insurance database in the United States

19-20 May 2011, Paris – France at Université Paris Descartes and Berkeley University Conferences

  • view > Evaluation and pricing of medical technologies – France/US
  • view > Biotechs in France and US: evolution or real change of the market?

2-4 March 2011, Saint-Etienne - France at ROADEF 2011: 12th Congress of the French Society for Operational Research and Decision Making

Oral Presentation

  • view > Development of a model to optimize strategies of patient management in stroke

 

Archives